Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDA Strategies for Schistosoma Mansoni in Tanzania
NCT02162875Completed
- Sponsor
- DBL Institute for Health Research and Development
- Start
- Mar 2011
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of praziquantel in intestinal schistosomiasis (6 arms), sponsored by DBL Institute for Health Research and Development. Primary endpoints: Effect of Mass drug administration on prevalence of Schistosoma mansoni among children and adults at 4 years and Effect of Mass drug administration on intensity of Schistosoma mansoni among children and adults at 4 years. Started Mar 2011; status: completed.
02
Drugs
praziquantel
03
Conditions
intestinal schistosomiasis
Beyond the preview
Go deeper on NCT02162875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162875.